<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bone disease with hyperthyroidism and thyroid hormone therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bone disease with hyperthyroidism and thyroid hormone therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bone disease with hyperthyroidism and thyroid hormone therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah E Sellmeyer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The adverse effects of hyperthyroidism on the skeleton were known before the advent of satisfactory treatment for hyperthyroidism. One of the first reports of hyperthyroid bone disease was in 1891 when von Recklinghausen described the "worm-eaten" appearance of the long bones of a young woman who died from hyperthyroidism [<a href="#rid1">1</a>]. With the introduction of antithyroid drugs and radioiodine in the 1940s, clinically apparent hyperthyroid bone disease became less common. However, bone density measurements demonstrate that bone loss is common in patients with overt hyperthyroidism and to a lesser extent in those with subclinical hyperthyroidism, whether caused by endogenous hyperthyroidism or excessive doses of thyroid hormone(s) (thyroxine [T4] or triiodothyronine [T3]).</p><p>This topic will review bone disease in patients with overt and subclinical hyperthyroidism. The clinical manifestations, diagnosis, and treatment of overt and subclinical hyperthyroidism are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a>.)</p><p class="headingAnchor" id="H4438769"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Thyroid hormone directly stimulates bone resorption in organ culture [<a href="#rid2">2</a>]. This action is mediated by nuclear triiodothyronine (T3) receptors, predominantly thyroid receptor (TR)-alpha-1, which has been found in rat and human osteoblast cell lines [<a href="#rid3">3-5</a>] and in osteoclasts derived from an osteoclastoma [<a href="#rid5">5</a>]. Thyroid hormone may affect bone calcium metabolism either by a direct action on osteoclasts or by acting on osteoblasts, which in turn mediate osteoclastic bone resorption [<a href="#rid6">6</a>]. Thyroid-stimulating hormone (TSH) may also have a direct effect on bone formation and bone resorption, mediated via the TSH receptor on osteoblast and osteoclast precursors [<a href="#rid7">7,8</a>]; this putative effect is, however, controversial, since bone loss appeared independent of TSH levels in the experiments in mice with a loss-of-function TSH receptor [<a href="#rid9">9</a>].</p><p>Increased serum interleukin-6 (IL-6) concentrations in hyperthyroid patients may also play a role in thyroid hormone-stimulated bone loss [<a href="#rid10">10</a>]. IL-6 stimulates osteoclast production and may be an effector of the action of parathyroid hormone (PTH) on bone. (See  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms", section on 'Multiple myeloma'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERT HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Overt hyperthyroidism is associated with accelerated bone remodeling, reduced bone density, osteoporosis, and an increase in fracture rate. The bone density changes may or may not be reversible with therapy. These changes in bone metabolism are associated with negative calcium balance, hypercalciuria, and rarely, hypercalcemia.</p><p class="headingAnchor" id="H3"><span class="h2">Bone density</span><span class="headingEndMark"> — </span>Bone loss is a uniform feature of overt hyperthyroidism [<a href="#rid11">11</a>]. The extent of the reduction in bone density in most studies of hyperthyroid patients ranges from 10 to 20 percent. The extent of the reversibility of bone loss with therapy is unclear. Studies that have looked at changes in bone density after treatment of hyperthyroidism have yielded variable results. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of studies demonstrated improvement in bone mineral density (BMD) with treatment of hyperthyroidism [<a href="#rid11">11</a>]. Within the first year after treatment, BMD was below age-matched controls (Z-score below 0). However, BMD was similar to age-matched controls one to four years after treatment of hyperthyroidism. A subsequent study also showed complete recovery [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, bone density was measured using dual-energy x-ray absorptiometry (DXA) technology at baseline and 12 months after definitive management of hyperthyroidism in 50 young patients (mean age 29.4 years) with hyperthyroidism and either bone pain or an elevation in serum alkaline phosphatase [<a href="#rid13">13</a>]. At baseline, 92 percent had low bone density. One year after treatment, bone density improved by 6 percent. However, bone density remained below aged-matched controls. Several other studies have also shown incomplete recovery [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional, population-based study of 5778 women without and 252 women with a self-reported history of hyperthyroidism, bone density was measured at the ultradistal forearm using DXA technology. Women with a history of hyperthyroidism had a higher prevalence of osteoporosis (adjusted odds ratio [OR] 1.5, 95% CI 1.1-2.0) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 61 hyperthyroid women compared with matched controls, high-resolution peripheral quantitative computed tomography (HRpQCT) of the radius revealed higher trabecular and lower cortical areas, lower volumetric bone density, and reduced cortical strength, which was reversed with treatment [<a href="#rid18">18</a>].</p><p></p><p>The variability in these results is likely due to differences in bone densitometry techniques, site of measurement, patient-specific factors (eg, duration and severity of hyperthyroidism prior to treatment, form of hyperthyroidism treatment, vitamin D sufficiency), and length of follow-up [<a href="#rid19">19,20</a>]. Taken together, the above data suggest that bone loss is incompletely reversible in some patients, and therefore, a past history of hyperthyroidism should be considered during an assessment of clinical risk factors for osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'</a>.)</p><p>Histomorphometric studies of iliac crest bone biopsies show a greater deleterious effect of hyperthyroidism on cortical as opposed to trabecular bone [<a href="#rid21">21,22</a>]. In one report, hyperthyroid patients had only a 2.7 percent reduction in trabecular bone volume, but there was a 40 percent increase in osteoclast resorption surfaces in cortical bone and a 32 percent increase in cortical bone porosity [<a href="#rid21">21</a>]. There was no change in osteoid volume (ie, no osteomalacia). </p><p>Three-dimensional reconstructions of the remodeling sequence have shown how these changes occur. In the normal remodeling sequence, osteoclastic resorption and osteoblastic bone formation are synchronized. In overt hyperthyroidism, osteoclastic resorption is stimulated out of proportion to osteoblastic remineralization [<a href="#rid23">23</a>]. Both resorption and formation occur rapidly; the normal cycle duration of approximately 200 days is halved. In addition, more surfaces are resorbing and forming. But with each cycle, there is more bone resorbed than formed, and this is associated with loss of mineralized bone with each remodeling cycle. In contrast, cycle length approximates 700 days in hypothyroid patients and is associated with an increase in mineralized bone.</p><p class="headingAnchor" id="H4"><span class="h2">Fracture risk</span><span class="headingEndMark"> — </span>Overt hyperthyroidism is a risk factor for fracture [<a href="#rid11">11,24-26</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study of over 230,000 patients (9217 of whom had low thyroid-stimulating hormone [TSH] [&lt;0.3 mU/L]) followed for a median 7.5 years, there was an increased incidence of major osteoporotic fracture (hip, clinical spine, humerus, forearm) in patients with low TSH (13.5 percent, compared with 6.9 percent in those with normal TSH) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">In a subgroup analysis of patients with overt hyperthyroidism, there was a significant increase in the risk of hip fracture (hazard ratio [HR] 1.14, 95% CI 1.01-1.29) but not major osteoporotic fracture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort study of 686 White women over age 65 years followed for a mean of 3.7 years, women with serum TSH concentrations of 0.1 mU/L or less at baseline were at increased risk for both hip and vertebral fracture (relative risk [RR] 3.6 and 4.5, respectively) [<a href="#rid27">27</a>]. Exogenous thyroid hormone therapy was not a risk factor for fracture in women with normal serum TSH concentrations, but a history of hyperthyroidism was a risk factor for hip fracture, even after adjustment for serum TSH concentration and BMD. Serum thyroxine (T4) was not measured, so the proportion of women with overt and subclinical hyperthyroidism is not known.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Symptomatic bone disease</span><span class="headingEndMark"> — </span>The majority of patients with hyperthyroidism and bone disease are asymptomatic unless fracture occurs. In one older study of 187 patients with hyperthyroidism, as an example, only 15 (8 percent) had symptoms, predominantly severe bone pain or fracture [<a href="#rid21">21</a>]. All were women and 80 percent were over the age of 50 years. Three-quarters had been hyperthyroid for less than a year. Radiographic studies demonstrated generalized osteoporosis with frequent vertebral compression fractures or hypertransparency of the spine in the absence of fracture.</p><p class="headingAnchor" id="H6"><span class="h2">Mineral metabolism</span><span class="headingEndMark"> — </span>The increased calcium release into the circulation due to the increased bone resorption has effects on mineral metabolism, which leads to negative calcium balance in hyperthyroid patients [<a href="#rid28">28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia occurs in up to 8 percent of patients [<a href="#rid29">29</a>]. However, increases in the serum ionized calcium concentration are more common [<a href="#rid30">30</a>]. The hypercalcemia suppresses the secretion of parathyroid hormone (PTH), leading to hypercalciuria, which protects against hypercalcemia but leads to a negative calcium balance and is a potential cause of nephrolithiasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low serum PTH concentrations reduce the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol) [<a href="#rid31">31</a>]. The decline in calcitriol production is compounded by an increase in calcitriol metabolism induced by hyperthyroidism [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low serum calcitriol concentrations diminish intestinal calcium (and phosphorous) absorption, resulting in fecal calcium loss. Malabsorption of calcium may be aggravated by steatorrhea and increased gut motility [<a href="#rid33">33</a>].</p><p></p><p>Biochemical markers of bone and mineral metabolism are also affected. The serum concentrations of alkaline phosphatase, osteocalcin, osteoprotegerin [<a href="#rid34">34</a>], and fibroblast growth factor-23 (FGF-23) [<a href="#rid35">35</a>] are increased in overt hyperthyroidism; they may remain high for months after treatment, presumably due to a persistent increase in osteoblastic activity [<a href="#rid28">28,36,37</a>]. Urinary excretion of bone resorption markers (collagen-derived pyridinium cross-links and urinary N-telopeptide of type 1 collagen) is increased and falls to normal after treatment [<a href="#rid28">28,38</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Treatment and prevention</span><span class="headingEndMark"> — </span>Overt hyperthyroidism should be treated in all patients. In a case-control study from Denmark, the increased fracture risk with hyperthyroidism was reduced to a nonsignificant risk in those patients who were treated with an antithyroid drug [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a> and  <a class="medical medical_review" href="/z/d/html/7840.html" rel="external">"Exogenous hyperthyroidism", section on 'Treatment'</a>.)</p><p>In addition to treating the hyperthyroidism, patients should be advised to have adequate amounts of calcium and vitamin D in their diets, typically 1000 to 1200 mg of calcium (total of diet and supplement) and 800 to 1000 international units of vitamin D (see  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis", section on 'Optimal intake'</a>). Calcium and vitamin D supplementation may be especially important in the setting of overt hyperthyroidism, since some data suggest that post-thyroidectomy hypocalcemia may be due in part to a pathophysiology similar to that seen in "hungry bone syndrome" following surgical correction of hyperparathyroidism [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/2070.html" rel="external">"Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"</a>.)</p><p>Some patients may benefit from bisphosphonates. In two studies, there was greater improvement in bone density after resolution of the hyperthyroidism when hyperthyroid women were treated with both <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> and <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> versus methimazole alone [<a href="#rid41">41,42</a>]. Fracture rate was not reported.</p><p>The decision to treat with bisphosphonates should be based upon fracture risk assessment. Fracture risk is determined by a combination of BMD and clinical risk factors. Patients at highest risk for fracture are the most likely to benefit from bisphosphonate therapy. Fracture risk assessment is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H15821433"><span class="h1">SUBCLINICAL HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Patients with subclinical hyperthyroidism have normal serum concentrations of free thyroxine (T4) and triiodothyronine (T3) but subnormal concentrations of thyroid-stimulating hormone (TSH). (See  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a>.)</p><p>Endogenous or exogenous subclinical hyperthyroidism is associated with reduced bone density, particularly in cortical-rich bone in postmenopausal women. The risk of fracture appears to be related to the degree of TSH suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture. (See <a class="local">'Fracture risk'</a> below.)</p><p>The causes of subclinical hyperthyroidism are the same as the causes of overt hyperthyroidism, and like overt hyperthyroidism, subclinical hyperthyroidism can be persistent or transient  (<a class="graphic graphic_table graphicRef76972" href="/z/d/graphic/76972.html" rel="external">table 1</a>). Common causes of subclinical hyperthyroidism include autonomously functioning thyroid adenomas and multinodular goiters (endogenous subclinical hyperthyroidism), Graves' disease (endogenous subclinical hyperthyroidism), or excessive thyroid hormone therapy (exogenous subclinical hyperthyroidism).</p><p class="headingAnchor" id="H8"><span class="h2">Endogenous subclinical hyperthyroidism: Nodular goiter and Graves' disease</span><span class="headingEndMark"> — </span>Any form of hyperthyroidism can be subclinical, but this disorder most commonly occurs in older patients with a multinodular goiter or, less often, mild Graves' disease.</p><p class="headingAnchor" id="H241042194"><span class="h3">Bone density</span><span class="headingEndMark"> — </span>Although symptomatic bone disease is not a feature of subclinical hyperthyroidism, observational data strongly suggest that this disorder has an adverse effect upon bone density and is a risk factor for osteoporosis [<a href="#rid43">43</a>].</p><p>The following studies illustrate the range of findings in women with subclinical hyperthyroidism due to nodular goiter or Graves' disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report, women with nodular goiter and subclinical hyperthyroidism had decreased forearm bone density, which correlated inversely with serum free T4 values (although in the normal range) [<a href="#rid44">44</a>]. In another report, postmenopausal (but not premenopausal) women with nodular goiter and subclinical hyperthyroidism had reduced bone density in the radius and femoral neck but not lumbar spine [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal women with subclinical hyperthyroidism treated with <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> had higher distal forearm bone density as compared with untreated women [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal women with subclinical hyperthyroidism treated with radioiodine and followed for two years did not lose bone from the spine or the hip, whereas untreated women lost bone at both sites (4.5 and 2.0 percent, respectively [p&lt;0.02]) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 284 patients with subclinical hyperthyroidism from six prospective, population-based cohorts that included 5458 individuals, the annual loss of femoral neck bone density was -0.59 percent greater among those with TSH &lt;0.1 mU/L compared with those who were euthyroid [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H241042201"><span class="h3">Fracture risk</span><span class="headingEndMark"> — </span>Endogenous subclinical hyperthyroidism increases the risk of fracture. In a meta-analysis of 13 prospective cohort studies, compared with euthyroidism, endogenous subclinical hyperthyroidism was associated with an increased risk of hip fracture (6.1 versus 4.4 percent; hazard ratio [HR] 1.52, 95% CI 1.19-1.93), any fracture (13.9 versus 8.4 percent; HR 1.42, 95% CI 1.16-1.74), and clinical spine fracture (2.3 versus 1.2 percent; HR 1.74, 95% CI 1.01-2.99) [<a href="#rid49">49</a>]. In this analysis, lower TSH levels (&lt;0.10 mU/L) were associated with higher fracture rates. In a prospective cohort study, for each six months in which the TSH was below 0.3 mU/L, hip fracture risk increased by 1.07 (95% CI 1.04-1.10) [<a href="#rid26">26</a>].</p><p>Subsequent studies similarly reported an association between endogenous subclinical hyperthyroidism and fracture risk:</p><p class="bulletIndent1"><span class="glyph">●</span>In a Swedish subcohort of the Osteoporotic Fractures in Men (MrOS) study (mean age 75), the 25 participants with subclinical hyperthyroidism (without <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> treatment) had an increased risk for vertebral fracture compared with euthyroid individuals (31.8 versus 9.2 percent, adjusted HR 3.12, 95% CI 1.37-7.12) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study of 10,946 individuals who experienced 3556 fractures with a median follow-up of 21 years, those with subclinical hyperthyroidism (TSH &lt;0.56 mIU/L) had a hazard ratio for fracture of 1.34 (95% CI 1.09-1.65) [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H4684381"><span class="h3">Mineral metabolism</span><span class="headingEndMark"> — </span>Among patients with Graves' hyperthyroidism taking an anti-thyroid drug, those with persistent subclinical hyperthyroidism (ie, the dose of antithyroid drug is insufficient to normalize serum TSH) have higher serum bone alkaline phosphatase concentrations and urinary pyridinoline excretion than those who are euthyroid [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H4684401"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>We typically treat the underlying cause of subclinical hyperthyroidism in patients at risk for skeletal complications, such as postmenopausal women with low bone density. There are no studies evaluating the long-term benefits of correcting subclinical hyperthyroidism, particularly studies with clinically important endpoints such as fracture. In two nonrandomized studies, postmenopausal women with nodular goiter and subclinical hyperthyroidism treated with antithyroid drugs or radioiodine for two years had higher bone density than similar women who were not treated [<a href="#rid46">46,47</a>]. The management of endogenous subclinical hyperthyroidism is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Endogenous subclinical hyperthyroidism'</a>.)</p><p>In addition to treating the underlying thyroid disease, lifestyle measures (adequate calcium and vitamin D, exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use) should be adopted universally to reduce bone loss in postmenopausal women. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Exogenous thyroid hormone therapy</span><span class="headingEndMark"> — </span>Thyroid hormone (T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>]) is administered in replacement doses for the treatment of hypothyroidism and in higher doses (suppression therapy) to patients with thyroid cancer. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Dose and monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a>.)</p><p>Many patients treated with T4 have iatrogenic subclinical hyperthyroidism, and some have increased bone resorption and reduced bone density. Fracture risk appears to be related to the degree of TSH suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture.</p><p class="headingAnchor" id="H10"><span class="h3">Bone density</span><span class="headingEndMark"> — </span>Many cross-sectional studies and a smaller number of longitudinal studies have found that patients, particularly postmenopausal women, with exogenous subclinical hyperthyroidism can have the same reduction in bone density as occurs in patients with endogenous subclinical hyperthyroidism, and that careful adjustment of the dose of T4 can minimize this risk. However, a reduction in bone density with suppressive doses of thyroid hormone is not a uniform finding [<a href="#rid53">53-60</a>].</p><p>In a meta-analysis of 17 studies of patients with thyroid cancer taking suppressive doses of <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>, postmenopausal women had a significant reduction in bone density of the lumbar spine and a nonsignificant trend in reduced bone density of the total hip, while premenopausal women had significant increases at both sites and bone density measurements in men were unchanged [<a href="#rid61">61</a>].</p><p>In premenopausal women taking T4, the annualized loss of femoral neck density is significantly correlated with dose, and bone density is not reduced if the T4 dose does not exceed approximately 2 mcg/kg body weight [<a href="#rid62">62</a>]. In contrast, postmenopausal women who are not on estrogen replacement and who are taking more than 1.6 mcg/kg body weight of T4 had significant bone loss in one study [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3901681760"><span class="h3">Bone geometry</span><span class="headingEndMark"> — </span>In a small study of 25 pre- and 74 postmenopausal women receiving T4 suppressive therapy for thyroid cancer for more than three years, compared with 297 controls, postmenopausal patients with free T4 concentrations greater than 1.79 ng/dL had lower cross-sectional moment of inertia, cross-sectional area, section modulus, and thinner cortical thickness (but not lower bone mineral density [BMD]) at the femoral neck [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H3099737372"><span class="h3">Fracture risk</span><span class="headingEndMark"> — </span>In some [<a href="#rid27">27,65</a>], but not all [<a href="#rid66">66,67</a>], studies, patients with subclinical hyperthyroidism due to exogenous thyroid hormone therapy have an increased risk of fracture. The contradictory findings are likely due to differences in the patient populations studied and to the degree of TSH suppression. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study of 17,684 individuals taking T4 in Tayside, Scotland, there was no increase in osteoporotic fractures in the 3731 individuals whose TSH was low but detectable (between 0.04 and 0.4 mU/L), while those with undetectable TSH (below 0.03 mU/L) had a twofold increased risk [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 686 women older than 65 years of age, women with a low TSH concentration (≤0.1 mU/L) had a nearly fourfold increased risk of hip and vertebral fracture compared with women who had normal serum TSH concentrations [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 1180 patients taking T4, 59 percent had a suppressed serum TSH concentration (&lt;0.05 mU/L) [<a href="#rid66">66</a>]. Over a five-year period, the overall fracture rate in the women over age 65 years was 2.5 percent in those with suppressed TSH values versus 0.9 percent in those with normal serum TSH values; this difference did not reach statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Cardiovascular Health Study of 4936 individuals over age 65 years, there was no association of subclinical hyperthyroidism and incident hip fracture [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of women on TSH-suppressive therapy for thyroid cancer, radiologic vertebral fractures were found in 44.6 percent of 83 women whose TSH target was &lt;0.5 mU/L, compared with 4.3 percent of 46 women whose TSH target was &gt;1 mU/L [<a href="#rid68">68</a>].</p><p></p><p>Thus, fracture risk appears to be related to the degree of TSH suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture.</p><p class="headingAnchor" id="H11"><span class="h3">Mineral metabolism</span><span class="headingEndMark"> — </span>Changes in several other measures of bone and mineral metabolism are also consistent with increased bone resorption in subclinical hyperthyroidism. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary excretion of bone collagen-derived pyridinium cross-links is increased in postmenopausal women [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative correlation has been demonstrated between the serum osteocalcin and TSH concentrations [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum carboxy-terminal-I-telopeptide (ICTP) concentrations are high more often than are serum osteocalcin concentrations in postmenopausal women taking suppressive doses of T4 [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum ICTP, urine N-terminal telopeptide of type I collagen, and serum osteocalcin were elevated in estrogen-deficient postmenopausal women, but not premenopausal women, when T4 dose was carefully titrated to prevent overzealous TSH suppression in patients with thyroid cancer [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Prevention and treatment of reduced bone density</span><span class="headingEndMark"> — </span>There are several measures that may prevent loss of bone density: titration of T4 therapy to lower doses, calcium supplementation, and inhibitors of bone resorption. (See  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Patients on T4 for the treatment of hypothyroidism'</a> and  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Patients on suppressive T4 therapy'</a>.)</p><p class="headingAnchor" id="H4439010"><span class="h4">Titration of T4</span><span class="headingEndMark"> — </span>In patients being treated for primary hypothyroidism, over-replacement of T4 should be avoided. A 1997 study demonstrated the benefit of titrating T4 dose to achieve a normal TSH. Both lumbar and femoral bone density increased, and serum osteocalcin and urinary excretion of bone collagen-derived pyridinium cross-links decreased, when the T4 dose was reduced in postmenopausal women whose initial serum TSH concentration was low [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Goals of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Over-replacement, reduced TSH'</a>.)</p><p>For patients treated with thyroid hormone suppression therapy for thyroid cancer, the degree of thyroid hormone suppression should be based on the risk of disease recurrence. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a>.)</p><p>Because of the adverse effects of suppressive doses of thyroid hormone on bone and the heart, the 2015 American Thyroid Association (ATA) management guidelines for thyroid nodules and differentiated thyroid cancer recommend against suppressive therapy for patients with thyroid nodules, and they suggest that patients with low-risk cancers be treated with T4 doses that target TSH values in the lower portion of the normal range [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H4439016"><span class="h4">Calcium supplementation</span><span class="headingEndMark"> — </span>Adequate dietary calcium intake is essential to ameliorate the adverse effects of thyroid hormone on bone. In a study of 46 postmenopausal women taking suppressive doses of T4, those taking placebo had 5 to 8 percent reductions in bone density over a two-year period, while those given 1000 mg of calcium daily had no measurable bone loss [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p class="headingAnchor" id="H4439073"><span class="h4">Inhibitors of bone resorption</span><span class="headingEndMark"> — </span>Treatment with inhibitors of bone resorption may be useful in patients with continuing bone loss. In short-term studies in humans, <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> reduced thyroid hormone-mediated increases in measures of bone turnover [<a href="#rid76">76,77</a>]. In one study of patients with thyroid cancer taking suppressive doses of T4, bone density was not reduced as compared with normal subjects but increased with cyclic pamidronate therapy [<a href="#rid77">77</a>]. In another study, <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> improved bone density in postmenopausal women with low BMD (T-score ≤-2.5), who were taking long-term thyroid hormone suppressive therapy for the treatment of thyroid cancer [<a href="#rid78">78</a>]. Alendronate was less effective in patients taking suppressive therapy for nine years than for those taking it three to six years. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis"</a>.)</p><p>Estrogen replacement therapy is protective when coadministered with thyroid hormone. In one study of 196 women taking thyroid hormone, significant reductions in bone density were found if the T4-equivalent dose was greater than 1.6 mcg/kg, but not at lower doses [<a href="#rid79">79</a>]. However, postmenopausal women who also were taking estrogen replacement therapy had no bone loss. The role of estrogen replacement therapy has been diminished since the Women's Health Initiative (WHI). This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">T4 REPLACEMENT THERAPY</span></p><p class="headingAnchor" id="H4439118"><span class="h2">Treatment of overt hypothyroidism</span><span class="headingEndMark"> — </span>Bone loss would not be expected to occur when hypothyroidism is treated with oral T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) and the serum thyroid-stimulating hormone (TSH) concentration does not go below the reference range (ie, if subclinical hyperthyroidism is avoided). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study, 50 women with primary or radioiodine-induced hypothyroidism receiving long-term therapy had no change in femoral neck or spine bone density [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 44 children with congenital hypothyroidism treated and followed for an average of 8.5 years, bone mineral density (BMD) did not differ compared with that of age-matched normal subjects [<a href="#rid81">81</a>].</p><p></p><p>However, hypothyroidism is associated with an <strong>increase</strong> in bone density, and treatment with T4 may result in transient increased bone resorption and a decrease in bone density, particularly in women [<a href="#rid63">63,82-84</a>]. This finding has not been reported in men [<a href="#rid85">85,86</a>].</p><p>In one study, 26 premenopausal hypothyroid women with Hashimoto's thyroiditis were treated with an average dose of 0.111 mg per day of T4 for an average of 7.5 years [<a href="#rid87">87</a>]. Serum TSH concentrations were normal throughout the study. The mean density of the femoral neck and trochanter were significantly lower than those of age-matched controls (-5.7 and -7 percent, respectively); lumbar spine BMD was similar in the two groups. This single study suggests that T4 replacement therapy may be sufficiently nonphysiologic that it could be associated with increased bone turnover; however, these data have yet to be confirmed.</p><p class="headingAnchor" id="H15"><span class="h2">Treatment of subclinical hypothyroidism</span><span class="headingEndMark"> — </span>In randomized trials of T4 replacement in predominantly postmenopausal women with subclinical hypothyroidism, there was either no reduction [<a href="#rid88">88</a>] or a very small reduction (1.2 percent after 48 weeks) [<a href="#rid89">89</a>] in bone density with normalization of serum TSH concentrations. (See  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H329486430"><span class="h1">THYROID HORMONE WITHIN THE NORMAL REFERENCE RANGE</span><span class="headingEndMark"> — </span>Several, but not all, cohort studies have found that low-normal thyroid-stimulating hormone (TSH) and high-normal free thyroxine (T4) levels, within their respective normal reference ranges, correlate with low bone mineral density (BMD) [<a href="#rid57">57</a>] or fracture [<a href="#rid90">90</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study from South Korea of 959 postmenopausal women, TSH within the normal range was positively correlated with lumbar spine and femoral neck bone density [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective study of 2374 postmenopausal women, free T4 within the normal range was negatively correlated with total hip BMD and nonvertebral fractures, as well as an increased rate of bone loss at the hip [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 2957 adults over age 45 from Taiwan, there was a negative correlation between free T4 and wrist BMD in women over age 50 years [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 56,835 individuals from several prospective cohorts, the hazard ratio (HR) for hip fracture was 1.25 (95% CI 1.05-1.49) for TSH 0.45 to 0.99 mU/L and 1.12 (95% CI 0.94-1.33) for TSH 2.50 to 3.49 mU/L [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 533 postmenopausal women, TSH was positively correlated with trabecular bone score [<a href="#rid91">91</a>]. Women who fractured during a five-year follow-up period had lower mean TSH levels than those who did not fracture (1.77 versus 2.05 mU/L).</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overt hyperthyroidism</strong> – Overt hyperthyroidism is associated with accelerated bone remodeling, reduced bone mineral density (BMD), osteoporosis, and an increase in fracture rate. Hyperthyroidism should be treated in all patients. (See <a class="local">'Overt hyperthyroidism'</a> above and  <a class="medical medical_review" href="/z/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/z/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a> and  <a class="medical medical_review" href="/z/d/html/7840.html" rel="external">"Exogenous hyperthyroidism", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical hyperthyroidism</strong> – Endogenous or exogenous subclinical hyperthyroidism is associated with reduced bone density, particularly in cortical-rich bone in postmenopausal women. The risk of fracture appears to be related to the degree of thyroid-stimulating hormone (TSH) suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture. (See <a class="local">'Subclinical hyperthyroidism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endogenous</strong> – We typically treat the underlying cause of endogenous subclinical hyperthyroidism in patients at risk for skeletal complications, such as postmenopausal women with low bone density. (See <a class="local">'Endogenous subclinical hyperthyroidism: Nodular goiter and Graves' disease'</a> above and  <a class="medical medical_review" href="/z/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exogenous</strong> – Thyroid hormone (T4 [<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>]) is administered in replacement doses for the treatment of hypothyroidism and in higher doses (suppression therapy) to patients with thyroid cancer. In patients being treated for primary hypothyroidism, over-replacement of T4 should be avoided. The risk of osteoporosis in postmenopausal women taking suppressive doses of T4 (levothyroxine) for thyroid cancer can be minimized by treatment with doses of T4 that yield serum TSH levels within the reference range in low-risk cancer patients and by institution of bisphosphonate therapy where indicated. (See <a class="local">'Prevention and treatment of reduced bone density'</a> above and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid hormone replacement therapy</strong> – Appropriate replacement therapy for hypothyroidism with avoidance of TSH suppression probably does not adversely alter skeletal metabolism. (See <a class="local">'T4 replacement therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">von Recklinghausen FD. Die Fibröse oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen, Festchrift Rudolf Virchow (Ed), George Reimer, Berlin 1891. p.1.</li><li><a class="nounderline abstract_t">Mundy GR, Shapiro JL, Bandelin JG, et al. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 1976; 58:529.</a></li><li><a class="nounderline abstract_t">Rizzoli R, Poser J, Bürgi U. Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 1986; 35:71.</a></li><li><a class="nounderline abstract_t">Sato K, Han DC, Fujii Y, et al. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3'-triiodo-L-thyronine nuclear receptors. Endocrinology 1987; 120:1873.</a></li><li><a class="nounderline abstract_t">Abu EO, Bord S, Horner A, et al. The expression of thyroid hormone receptors in human bone. Bone 1997; 21:137.</a></li><li><a class="nounderline abstract_t">Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994; 134:169.</a></li><li><a class="nounderline abstract_t">Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115:151.</a></li><li><a class="nounderline abstract_t">Sun L, Zhu LL, Lu P, et al. Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton. Proc Natl Acad Sci U S A 2013; 110:9891.</a></li><li><a class="nounderline abstract_t">Bassett JH, O'Shea PJ, Sriskantharajah S, et al. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007; 21:1095.</a></li><li><a class="nounderline abstract_t">Lakatos P, Foldes J, Horvath C, et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82:78.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. Thyroid 2003; 13:585.</a></li><li><a class="nounderline abstract_t">Karga H, Papapetrou PD, Korakovouni A, et al. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61:466.</a></li><li><a class="nounderline abstract_t">Udayakumar N, Chandrasekaran M, Rasheed MH, et al. Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006; 47:947.</a></li><li><a class="nounderline abstract_t">Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992; 75:1531.</a></li><li><a class="nounderline abstract_t">Grant DJ, McMurdo ME, Mole PA, Paterson CR. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol (Oxf) 1995; 43:339.</a></li><li><a class="nounderline abstract_t">Jyotsna VP, Sahoo A, Ksh SA, et al. Bone mineral density in patients of Graves disease pre- &amp; post-treatment in a predominantly vitamin D deficient population. Indian J Med Res 2012; 135:36.</a></li><li><a class="nounderline abstract_t">Svare A, Nilsen TI, Bjøro T, et al. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol 2009; 161:779.</a></li><li><a class="nounderline abstract_t">Nicolaisen P, Obling ML, Winther KH, et al. Consequences of Hyperthyroidism and Its Treatment for Bone Microarchitecture Assessed by High-Resolution Peripheral Quantitative Computed Tomography. Thyroid 2021; 31:208.</a></li><li><a class="nounderline abstract_t">El Hadidy el HM, Ghonaim M, El Gawad SSh, El Atta MA. Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMC Endocr Disord 2011; 11:15.</a></li><li><a class="nounderline abstract_t">Karunakaran P, Maharajan C, Chockalingam R, et al. The effect of total thyroidectomy on the recovery of bone mineral density in subjects with hyperthyroidism. Surgery 2019; 165:80.</a></li><li><a class="nounderline abstract_t">Meunier PJ, S-Bianchi GG, Edouard CM, et al. Bony manifestations of thyrotoxicosis. Orthop Clin North Am 1972; 3:745.</a></li><li><a class="nounderline abstract_t">Mosekilde L, Melsen F, Bagger JP, et al. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) 1977; 85:515.</a></li><li><a class="nounderline abstract_t">Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7:379.</a></li><li><a class="nounderline abstract_t">Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.</a></li><li><a class="nounderline abstract_t">Wejda B, Hintze G, Katschinski B, et al. Hip fractures and the thyroid: a case-control study. J Intern Med 1995; 237:241.</a></li><li><a class="nounderline abstract_t">Abrahamsen B, Jørgensen HL, Laulund AS, et al. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J Bone Miner Res 2014; 29:2040.</a></li><li><a class="nounderline abstract_t">Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134:561.</a></li><li><a class="nounderline abstract_t">Pantazi H, Papapetrou PD. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 2000; 85:1099.</a></li><li><a class="nounderline abstract_t">Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19:35.</a></li><li><a class="nounderline abstract_t">Frizel D, Malleson A, Marks V. Plasma levels of ionised calcium and magnesium in thyroid disease. Lancet 1967; 1:1360.</a></li><li><a class="nounderline abstract_t">Jastrup B, Mosekilde L, Melsen F, et al. Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism. Metabolism 1982; 31:126.</a></li><li><a class="nounderline abstract_t">Karsenty G, Bouchard P, Ulmann A, Schaison G. Elevated metabolic clearance rate of 1 alpha,25-dihydroxyvitamin D3 in hyperthyroidism. Acta Endocrinol (Copenh) 1985; 110:70.</a></li><li><a class="nounderline abstract_t">Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 1973; 78:669.</a></li><li><a class="nounderline abstract_t">Amato G, Mazziotti G, Sorvillo F, et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004; 35:785.</a></li><li><a class="nounderline abstract_t">Park SE, Cho MA, Kim SH, et al. The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease. Clin Endocrinol (Oxf) 2007; 66:854.</a></li><li><a class="nounderline abstract_t">Cooper DS, Kaplan MM, Ridgway EC, et al. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 1979; 90:164.</a></li><li><a class="nounderline abstract_t">Garrel DR, Delmas PD, Malaval L, Tourniaire J. Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 1986; 62:1052.</a></li><li><a class="nounderline abstract_t">MacLeod JM, McHardy KC, Harvey RD, et al. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol (Oxf) 1993; 38:49.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 2005; 77:139.</a></li><li><a class="nounderline abstract_t">Karunakaran P, Maharajan C, Ramalingam S, Rachmadugu SV. Is hungry bone syndrome a cause of postoperative hypocalcemia after total thyroidectomy in thyrotoxicosis? A prospective study with bone mineral density correlation. Surgery 2018; 163:367.</a></li><li><a class="nounderline abstract_t">Lupoli G, Nuzzo V, Di Carlo C, et al. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 1996; 10:343.</a></li><li><a class="nounderline abstract_t">Yang LJ, Shen FX, Zheng JC, Zhang HL. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism]. Zhongguo Gu Shang 2012; 25:133.</a></li><li><a class="nounderline abstract_t">Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest 2018; 41:99.</a></li><li><a class="nounderline abstract_t">Mudde AH, Reijnders FJ, Kruseman AC. Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol (Oxf) 1992; 37:35.</a></li><li><a class="nounderline abstract_t">Földes J, Tarján G, Szathmari M, et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf) 1993; 39:521.</a></li><li><a class="nounderline abstract_t">Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994; 41:421.</a></li><li><a class="nounderline abstract_t">Faber J, Jensen IW, Petersen L, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998; 48:285.</a></li><li><a class="nounderline abstract_t">Segna D, Bauer DC, Feller M, et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J Intern Med 2018; 283:56.</a></li><li><a class="nounderline abstract_t">Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 2015; 313:2055.</a></li><li><a class="nounderline abstract_t">Svensson J, Ohlsson C, Karlsson MK, et al. Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men. Osteoporos Int 2021; 32:2257.</a></li><li><a class="nounderline abstract_t">Daya NR, Fretz A, Martin SS, et al. Association Between Subclinical Thyroid Dysfunction and Fracture Risk. JAMA Netw Open 2022; 5:e2240823.</a></li><li><a class="nounderline abstract_t">Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000; 85:4157.</a></li><li><a class="nounderline abstract_t">de Melo TG, da Assumpção LV, Santos Ade O, Zantut-Wittmann DE. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Res 2015; 8:7.</a></li><li><a class="nounderline abstract_t">Kim CW, Hong S, Oh SH, et al. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. J Bone Metab 2015; 22:135.</a></li><li><a class="nounderline abstract_t">Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. J Endocrinol 2012; 213:209.</a></li><li><a class="nounderline abstract_t">Papaleontiou M, Hawley ST, Haymart MR. Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients. Oncologist 2016; 21:165.</a></li><li><a class="nounderline abstract_t">Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013; 98:3562.</a></li><li><a class="nounderline abstract_t">Kim DJ, Khang YH, Koh JM, et al. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxf) 2006; 64:86.</a></li><li><a class="nounderline abstract_t">Murphy E, Glüer CC, Reid DM, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 2010; 95:3173.</a></li><li><a class="nounderline abstract_t">Lin JD, Pei D, Hsia TL, et al. The relationship between thyroid function and bone mineral density in euthyroid healthy subjects in Taiwan. Endocr Res 2011; 36:1.</a></li><li><a class="nounderline abstract_t">Ku EJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2021; 106:3655.</a></li><li><a class="nounderline abstract_t">Garton M, Reid I, Loveridge N, et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf) 1994; 41:747.</a></li><li><a class="nounderline abstract_t">Ribot C, Tremollieres F, Pouilles JM, Louvet JP. Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf) 1990; 33:143.</a></li><li><a class="nounderline abstract_t">Moon JH, Jung KY, Kim KM, et al. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma. Bone 2016; 83:104.</a></li><li><a class="nounderline abstract_t">Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95:186.</a></li><li><a class="nounderline abstract_t">Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992; 37:500.</a></li><li><a class="nounderline abstract_t">Garin MC, Arnold AM, Lee JS, et al. Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab 2014; 99:2657.</a></li><li><a class="nounderline abstract_t">Mazziotti G, Formenti AM, Frara S, et al. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. J Clin Endocrinol Metab 2018; 103:956.</a></li><li><a class="nounderline abstract_t">Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991; 72:1189.</a></li><li><a class="nounderline abstract_t">Ross DS, Ardisson LJ, Nussbaum SR, Meskell MJ. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 1991; 72:507.</a></li><li><a class="nounderline abstract_t">Loviselli A, Mastinu R, Rizzolo E, et al. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997; 7:561.</a></li><li><a class="nounderline abstract_t">Mikosch P, Obermayer-Pietsch B, Jost R, et al. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 2003; 13:347.</a></li><li><a class="nounderline abstract_t">Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 1997; 46:301.</a></li><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li><li><a class="nounderline abstract_t">Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81:1232.</a></li><li><a class="nounderline abstract_t">Rosen HN, Moses AC, Gundberg C, et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993; 77:664.</a></li><li><a class="nounderline abstract_t">Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998; 83:2324.</a></li><li><a class="nounderline abstract_t">Panico A, Lupoli GA, Fonderico F, et al. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. Thyroid 2009; 19:437.</a></li><li><a class="nounderline abstract_t">Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA 1994; 271:1245.</a></li><li><a class="nounderline abstract_t">Hanna FW, Pettit RJ, Ammari F, et al. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf) 1998; 48:229.</a></li><li><a class="nounderline abstract_t">Leger J, Ruiz JC, Guibourdenche J, et al. Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 1997; 86:704.</a></li><li><a class="nounderline abstract_t">Krølner B, Jørgensen JV, Nielsen SP. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 1983; 18:439.</a></li><li><a class="nounderline abstract_t">Coindre JM, David JP, Rivière L, et al. Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med 1986; 146:48.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Weeke J, Hoeck HC, et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 2000; 10:335.</a></li><li><a class="nounderline abstract_t">Toh SH, Brown PH. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Miner Res 1990; 5:463.</a></li><li><a class="nounderline abstract_t">Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 1995; 155:2005.</a></li><li><a class="nounderline abstract_t">Kung AW, Pun KK. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 1991; 265:2688.</a></li><li><a class="nounderline abstract_t">Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med 1993; 95:385.</a></li><li><a class="nounderline abstract_t">Meier C, Beat M, Guglielmetti M, et al. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 2004; 15:209.</a></li><li><a class="nounderline abstract_t">Aubert CE, Floriani C, Bauer DC, et al. Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts. J Clin Endocrinol Metab 2017; 102:2719.</a></li><li><a class="nounderline abstract_t">Vendrami C, Marques-Vidal P, Gonzalez Rodriguez E, et al. Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort. Osteoporos Int 2022; 33:195.</a></li></ol></div><div id="topicVersionRevision">Topic 7882 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : von Recklinghausen FD. Die Fibröse oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen, Festchrift Rudolf Virchow (Ed), George Reimer, Berlin 1891. p.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/182721" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Direct stimulation of bone resorption by thyroid hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3001477" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nuclear thyroid hormone receptors in cultured bone cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3569118" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3'-triiodo-L-thyronine nuclear receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267688" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The expression of thyroid hormone receptors in human bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275930" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567913" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : TSH is a negative regulator of skeletal remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716650" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Genetic confirmation for a central role for TNFαin the direct action of thyroid stimulating hormone on the skeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327419" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989237" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum interleukin-6 and bone metabolism in patients with thyroid function disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930603" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473879" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bone mineral density in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075661" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of bone mineral density in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464660" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586604" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382181" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bone mineral density in patients of Graves disease pre-&amp;post-treatment in a predominantly vitamin D deficient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671706" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703114" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Consequences of Hyperthyroidism and Its Treatment for Bone Microarchitecture Assessed by High-Resolution Peripheral Quantitative Computed Tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21819612" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415871" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effect of total thyroidectomy on the recovery of bone mineral density in subjects with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bony manifestations of thyrotoxicosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/577336" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3536460" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862179" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891045" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hip fractures and the thyroid: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723381" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12803168" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk for fracture in women with low serum levels of thyroid-stimulating hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720046" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2192868" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of thyroid hormones on bone and mineral metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4165179" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Plasma levels of ionised calcium and magnesium in thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978987" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3839963" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Elevated metabolic clearance rate of 1 alpha,25-dihydroxyvitamin D3 in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4711771" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15336617" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437520" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/582089" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Alkaline phosphatase isoenzyme patterns in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485649" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Serum bone Gla protein: a marker of bone turnover in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435885" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151671" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146231" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Is hungry bone syndrome a cause of postoperative hypocalcemia after total thyroidectomy in thyrotoxicosis? A prospective study with bone mineral density correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915664" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577718" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28853052" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Thyroid diseases and bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424190" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Peripheral bone density in women with untreated multinodular goitre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252739" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955452" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578817" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29034571" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010634" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subclinical thyroid dysfunction and fracture risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34013460" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36346629" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Association Between Subclinical Thyroid Dysfunction and Fracture Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095447" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26097507" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26389089" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454529" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The skeletal consequences of thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26659220" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824418" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16402934" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410228" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226562" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The relationship between thyroid function and bone mineral density in euthyroid healthy subjects in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34302730" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7889610" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2225474" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bone mineral density and thyroid hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518742" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906785" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1286519" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24878045" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29121201" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2026741" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991818" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292943" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804103" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156039" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772604" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370687" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661603" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415993" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848399" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579237" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of replacement doses of thyroxine on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240877" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6603290" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510598" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Bone loss in hypothyroidism with hormone replacement. A histomorphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807062" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fractures in patients with primary idiopathic hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195844" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575055" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Thyroid hormone use and bone mineral density in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2023349" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213870" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727010" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28482002" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34409507" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
